Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GRFS — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

2.72

Margin Of Safety %

57

Put/Call OI Ratio

0.4

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.37

Price

7.5

Target Price

14.32

Analyst Recom

1

Performance Q

-17.05

Upside

213.1%

Beta

0.72

Ticker: GRFS




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-02-27GRFS9.060.360.002045
2026-03-03GRFS8.650.381.622078
2026-03-04GRFS8.650.420.362316
2026-03-06GRFS8.590.42999.992323
2026-03-09GRFS8.750.421.202323
2026-03-10GRFS8.190.422.432328
2026-03-11GRFS8.020.4322.002352
2026-03-12GRFS7.970.44999.992380
2026-03-13GRFS7.970.44999.992380
2026-03-17GRFS8.020.381.002328
2026-03-18GRFS7.860.380.022332
2026-03-20GRFS7.570.36999.992381
2026-03-25GRFS7.690.400.132108
2026-03-26GRFS7.620.400.502124
2026-03-27GRFS7.490.400.062130
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-02-27GRFS9.06- - 1.01
2026-03-02GRFS9.10- - 1.20
2026-03-03GRFS8.64- - 1.20
2026-03-04GRFS8.66- - 1.20
2026-03-05GRFS8.59- - 1.20
2026-03-06GRFS8.60- - 1.20
2026-03-09GRFS8.75- - 1.20
2026-03-10GRFS8.20- - 1.20
2026-03-11GRFS8.03- - 1.20
2026-03-12GRFS7.97- - 1.20
2026-03-13GRFS7.80- - 1.20
2026-03-17GRFS8.02- - 1.20
2026-03-18GRFS7.87- - 1.20
2026-03-19GRFS7.77- - 1.20
2026-03-20GRFS7.58- - 1.20
2026-03-23GRFS7.68- - 1.20
2026-03-24GRFS7.58- - 1.20
2026-03-25GRFS7.69- - 1.20
2026-03-26GRFS7.62- - 1.20
2026-03-27GRFS7.50- - 1.20
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-02-27GRFS0-0.662.51
2026-03-02GRFS0-0.682.51
2026-03-03GRFS0-0.682.51
2026-03-04GRFS0-0.682.51
2026-03-05GRFS0-0.680
2026-03-06GRFS0-0.682.51
2026-03-09GRFS0-1.152.51
2026-03-10GRFS0-1.152.51
2026-03-11GRFS0-1.152.75
2026-03-12GRFS0-1.152.75
2026-03-13GRFS0-1.152.75
2026-03-17GRFS0-1.382.75
2026-03-18GRFS0-1.382.75
2026-03-19GRFS0-1.382.75
2026-03-20GRFS0-1.382.75
2026-03-23GRFS0-1.642.75
2026-03-24GRFS0-1.642.75
2026-03-25GRFS0-1.642.72
2026-03-26GRFS0-1.642.72
2026-03-27GRFS0-1.642.72
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.64

Beta

0.72

Average Sales Estimate Current Quarter

1904

Average Sales Estimate Next Quarter

Fair Value

11.76

Quality Score

92

Growth Score

89

Sentiment Score

43

Actual DrawDown %

60.7

Max Drawdown 5-Year %

-70.7

Target Price

14.32

P/E

11.11

Forward P/E

5.69

PEG

0.24

P/S

0.23

P/B

0.82

P/Free Cash Flow

2.18

EPS

0.67

Average EPS Est. Cur. Y​

1.2

EPS Next Y. (Est.)

1.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.39

Relative Volume

1.37

Return on Equity vs Sector %

-20.2

Return on Equity vs Industry %

-29.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

GRFS Healthcare
$7.49
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
13/25
Volume
3/15
Valuation
18/20
TP/AR
2/10
Options
7/10
RSI
30.3
Range 1M
6.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
52 /100
WEAK
Momentum
13/25
Growth
21/30
Estimates
6/20
Inst/Vol
3/15
Options
9/10
EPS Yr
19.6%
EPS NY
30.2%
52W%
26.4%
💎
Long-Term Value
Quality companies, undervalued
63 /100
WATCH
🟢 BUY +349.8% upside
Quality
13/30
Valuation
28/30
Growth
14/25
Stability
4/10
LT Trend
4/5
Upside
+349.8%
Quality
92
MoS
57%
Grifols, S.A.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 25258
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
GRFS

Latest News

Caricamento notizie per GRFS
stock quote shares GRFS – Grifols, S.A. Stock Price stock today
news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025
marketwatch GRFS – Grifols, S.A. yahoo finance google finance
stock history GRFS – Grifols, S.A. invest stock market
stock prices GRFS premarket after hours
ticker GRFS fair value insiders trading